Compare ABG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABG | IMVT |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.3B |
| IPO Year | N/A | N/A |
| Metric | ABG | IMVT |
|---|---|---|
| Price | $234.19 | $27.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $261.29 | $27.75 |
| AVG Volume (30 Days) | 180.0K | ★ 2.0M |
| Earning Date | 01-29-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.57 | N/A |
| EPS | ★ 28.52 | N/A |
| Revenue | ★ $17,827,000,000.00 | N/A |
| Revenue This Year | $7.08 | N/A |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | $8.31 | ★ N/A |
| Revenue Growth | ★ 8.07 | N/A |
| 52 Week Low | $201.68 | $12.72 |
| 52 Week High | $312.56 | $27.69 |
| Indicator | ABG | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 66.83 |
| Support Level | $222.18 | $25.84 |
| Resistance Level | $247.16 | $27.69 |
| Average True Range (ATR) | 7.92 | 1.39 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 47.23 | 86.63 |
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 152 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly Texas, the West, the Mid-Atlantic, and the Southeast). Asbury store brands include McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated $17.2 billion of revenue in 2024 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.